SequelSEC

Anebulo Pharmaceuticals, Inc. ANEB

Pharmaceutical Preparations · CIK 0001815974 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-06-30
Operating income
-$9.22M
Fiscal year ended 2025-06-30
Free cash flow
Unavailable
Fiscal year ended 2025-06-30

Valuation, from the filing

Public float$15.06MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$0.37Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity1.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

Anebulo Pharmaceuticals, Inc. (ANEB) reported net income of -$8.48M for the fiscal year ended 2025-06-30. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Anebulo Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Anebulo Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-302022-06-302021-06-30
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$9.22M-$8.31M-$11.78M-$6.83M-$3.61M
Net income-$8.48M-$8.20M-$11.73M-$6.83M-$30.25M
Research & development$4.30M$3.55M$5.60M$2.96M$2.27M
Weighted-average diluted sharesshares 33.82Mshares 25.82Mshares 25.07Mshares 23.34MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable-$3.61M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.25$-0.32$-0.47$0.29Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.92M$4.76M$6.18M$3.87M$1.34M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Anebulo Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-302022-06-302021-06-30
Cash & equivalents$11.63M$3.09M$11.25MUnavailableUnavailable
Total assets$12.15M$4.07M$11.67M$15.58M$21.65M
Current assets$11.96M$3.51M$11.67MUnavailableUnavailable
Total liabilities$487.69K$260.58K$1.07M$512.53K$241.63K
Current liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailable
Total equity incl. NCI$11.66M$3.81M$10.60M$15.07M$21.41M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$224.18K$156.43K$534.54K$380.83K$110.05K

Cash flow

Anebulo Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-302022-06-302021-06-30
Operating cash flow-$6.35M-$8.09M-$9.68M-$5.44M-$4.87M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$14.88M-$62.35K$6.38MUnavailable$21.83M
Net change in cash$8.53M-$8.15M-$3.30M-$5.44M$16.96M
Stock-based compensation$1.45M$758.88K$884.72K$480.66K$199.95K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Anebulo Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-302022-06-302021-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailableUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ANEB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-13View SEC filing
10-Q · Filed 2025-02-14View SEC filing
10-Q · Filed 2024-11-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.